32 results on '"Buccisano, Francesco"'
Search Results
2. Review for "A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia"
3. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel
4. Flow Cytometric Identification and Enumeration of Monocyte Subsets in Bovine and Water Buffalo Peripheral Blood
5. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia
6. ESCCA / ISCCA protocol for the analysis of cerebrospinal fluid by multiparametric flow‐cytometry in hematological malignancies
7. The ISCCA flow protocol for the monitoring of anti‐CD20 therapies in autoimmune disorders
8. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
9. Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment
10. Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations
11. Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS)
12. Longitudinal detection ofDNMT3AR882Htranscripts in patients with acute myeloid leukemia
13. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems
14. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia
15. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
16. A cluster ofGeotrichum clavatum(Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature
17. Deferasirox chelation therapy in patients with transfusion‐dependent MDS: a ‘real‐world’ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata
18. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia
19. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes
20. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile
21. Azacitidine for the treatment of patients with acute myeloid leukemia
22. The genotype nucleophosmin mutated and FLT3‐ITD negative is characterized by high bax/bcl‐2 ratio and favourable outcome in acute myeloid leukaemia
23. Evaluation of the prognostic relevance of l‐selectin and ICAM1 expression in myelodysplastic syndromes
24. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
25. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia
26. Signature of B‐CLL with different prognosis by Shrunken centroids of surface antigen expression profiling
27. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*
28. P‐glycoprotein and BCL‐2 levels predict outcome in adult acute lymphoblastic leukaemia
29. Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr
30. Minimally differentiated acute myeloid leukaemia (AML-MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases
31. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.
32. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.